The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia. - Wikidata - wikimedia - TriplyDB

The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.

The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.

http://www.wikidata.org/entity/Q34999299

about

Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia.Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia.Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia.Improvement in process of care and outcome in patients requiring intensive care unit admission for community acquired pneumonia.Choosing the right combination therapy in severe community-acquired pneumonia Lung inflammatory pattern and antibiotic treatment in pneumonia Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.Year in review 2005: Critical Care--respirology: mechanical ventilation, infection, monitoring, and education.Severe community-acquired pneumonia: approach to therapy.Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.Bacteraemic pneumococcal pneumonia: current therapeutic options.Clinical review: What are the best hemodynamic targets for noncardiac surgical patients?What Is New in Antibiotic Therapy in Community-Acquired Pneumonia? An Evidence-Based Approach Focusing on Combined Therapy.Combination antibiotic therapy for community-acquired pneumonia.Do fluoroquinolones actually increase mortality in community-acquired pneumonia?Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities.Management of Community-acquired Pneumonia in Adults

P2860

Q30426227-FA4D2CC5-A070-4267-848D-6470391483D1 Q33749940-A156851D-E176-4E85-A79A-2169572B4513 Q33790704-D3991978-8595-4239-9714-31826B7140B4 Q33943151-F844C9D1-D3BF-471D-8140-0506A68D942E Q34696258-320FD3D4-E7DB-4E83-9F7C-FE3DA57E2CC2 Q34999131-05739B72-55F2-4F8A-B9AE-5CF1F5112682 Q35083508-C4DD578C-1018-431B-8500-C034CDD92EDC Q36072425-1AFB92D0-BD9D-4AE5-BAFF-4C8CEC84E3C2 Q36281234-DF2E2BF3-5C06-42FC-973C-01D205CBEE7A Q36295507-60FA1848-990D-4967-AAF2-B9F1D12B6304 Q36526019-0EC2F2C1-0835-45CC-A298-66D6402D64D7 Q36765778-59335185-BC13-4237-8C79-B70F271EED1B Q37482479-269336C1-94FD-4DBE-823E-1FC24BEB1AA3 Q37833059-B511AD71-07C6-4C50-9FFA-B926BA089913 Q38106770-DF9497F2-327B-4669-B47B-BCB64A90BD57 Q38571891-CABB9501-0AAD-4FD4-86C4-04090EEDC20F Q40075066-C027A2B2-6189-43FA-ADE0-A78E5E96534E Q43244601-416D0C68-BA35-48F2-879E-D8CC4CFC8890 Q55411506-38366495-9A39-4C6F-BE0F-04AFD5083BF9 Q57237808-5227E767-D349-4C7E-A21E-0612AEE2C03F

P2860

The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.

http://www.wikidata.org/entity/Q34999299

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

The impact of empiric antimicr ...... talized with severe pneumonia.

@ast

The impact of empiric antimicr ...... talized with severe pneumonia.

@en

The impact of empiric antimicr ...... talized with severe pneumonia.

@nl

type

label

The impact of empiric antimicr ...... talized with severe pneumonia.

@ast

The impact of empiric antimicr ...... talized with severe pneumonia.

@en

The impact of empiric antimicr ...... talized with severe pneumonia.

@nl

prefLabel

The impact of empiric antimicr ...... talized with severe pneumonia.

@ast

The impact of empiric antimicr ...... talized with severe pneumonia.

@en

The impact of empiric antimicr ...... talized with severe pneumonia.

@nl

P1433

Q34999299-0AAB21A2-8908-4540-B654-98E89F3F6B92

P1476

Q34999299-E971285F-D925-43C7-A145-7CB044E614E4

P2093

Q34999299-60B2AF6F-C06F-42DC-8B30-F187BC6CA863

Q34999299-AD303D08-959E-4776-8A6A-6F529FD84048

Q34999299-D7037C9A-8338-4BA5-882D-3A5783205761

P2860

Q34999299-030CFF14-655B-4FC6-BD56-439576F269AA

Q34999299-1A4FA25E-15AF-4737-BA65-13175654C0CE

Q34999299-379048BB-657B-4DC7-83CD-FF098D041FAA

Q34999299-3C9196AF-AD35-4EF1-B235-EF9DA6C4E3D5

Q34999299-414EB34F-4963-4AC9-9F59-DD9B1D0DA08D

Q34999299-4F6B2D8D-A7C7-4BAA-A31D-D6FC976A5369

Q34999299-4FE8D539-73F6-41D8-BBB2-42E2ACA30D01

Q34999299-58C33FC2-46CB-498A-A27B-DB69DBC276E0

Q34999299-5B5CE947-D21F-420C-9D91-C2754E7D749D

Q34999299-7ABDD379-2313-4E4E-B377-1E01DE705114

P2888

Q34999299-0FF5FE02-A991-4E07-B922-43A7D1D35044

P304

Q34999299-ED3244C3-CA17-47A5-978D-67732A879EBA

P31

Q34999299-504E03A3-9DC8-43D8-A78A-06BFD0F7D8DA

P356

Q34999299-5C01C6C6-79B6-46A7-91C2-D918C76C3B0A

P433

Q34999299-86B0C230-D75C-4918-9904-04E6C340B9A6

P478

Q34999299-A3C3D41F-7334-42B9-B0E0-1864C253631D

P50

Q34999299-38C5F714-7E0C-4150-9B47-9028F114773A

P577

Q34999299-682294F3-6D87-49AC-A8A7-993EA2432875

P5875

Q34999299-EE0C9DA6-EB40-4D0B-A65C-F99554DAD93B

P698

Q34999299-BF54185E-C5BF-47D2-981B-355DE451A5E0

P921

Q34999299-03E45B50-4EFA-44CF-9E89-00DD57C5B9DE

P932

Q34999299-003E34D1-C881-4BF4-9D89-EE3D69075885

P356

P1433

P1476

The impact of empiric antimicr ...... talized with severe pneumonia.

@en

P2093

Eric M Mortensen

http://www.w3.org/2001/XMLSchema#string

Jacqueline Pugh

http://www.w3.org/2001/XMLSchema#string

Marcos I Restrepo

http://www.w3.org/2001/XMLSchema#string

P2860

BTS Guidelines for the Management of Community Acquired Pneumonia in Adults

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

A prediction rule to identify low-risk patients with community-acquired pneumonia

Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.

Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.

Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia.

Anti-inflammatory effects of macrolide antibiotics.

Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study.

Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls.

Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.

P2888

P304

R8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC3934

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Anzueto

P577

2005-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7351263

http://www.w3.org/2001/XMLSchema#string

P698

16420641

http://www.w3.org/2001/XMLSchema#string

P921

hospitalization

P932

1550860

http://www.w3.org/2001/XMLSchema#string